Dipak Datta

3.3k citations
84 papers · 2.5k indexed · h-index 30

Dipak Datta

82 papers receiving 2.4k citations

Peers

Dipak Datta
Comparison fields: 5 of 119
  • Oncology 691
  • Immunology 469
  • Transplantation 55
  • Cancer Research 287
  • Molecular Biology 1.1k
Replace Alakananda Basu with:
Alakananda Basu United States
Hemant K. Bid India
Zhi Shi China
Georg Krupitza Austria
Marie‐Véronique Clement Singapore
Tomoko Oh‐hara Japan
Antonina Azzolina Italy
Reza Bayat Mokhtari Canada
Eleonora Turrini Italy
Astrid A. Ruefli Australia
Dipak Datta relative to Alakananda Basu United States Alakananda Basu's profile →
Citations per field
00.5×1.5×
Alakananda Basu · 1×
Citations per year

Countries citing papers authored by Dipak Datta

Since Specialization
Citations

This map shows the geographic impact of Dipak Datta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dipak Datta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dipak Datta more than expected).

Fields of papers citing papers by Dipak Datta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dipak Datta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dipak Datta. The network helps show where Dipak Datta may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Dipak Datta, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Dipak Datta Line = papers co-authored together Dipak Datta links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20241
3 20243
4 20242
5 202316
6 202311
7 202221
8 202126
9 201718
10 201734
11 201720
12 201657
13 201419
14 201211
15 201161
16
Hepatoprotective Activity of Bombax ceiba Linn against Isoniazid and Rifampicin-induced Toxicity in Experimental Rats
201036
17 200954
18 200856
19 200844
20 2006142

About Dipak Datta

Dipak Datta is a scholar working on Cancer Research, Molecular Biology and Oncology, having authored 84 papers that have together received 2.5k indexed citations. Recurring topics across this work include RNA modifications and cancer (10 papers), Immunotherapy and Immune Responses (8 papers), Epigenetics and DNA Methylation (6 papers), Chemokine receptors and signaling (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), RNA and protein synthesis mechanisms (5 papers), Nanoparticle-Based Drug Delivery (5 papers) and Autophagy in Disease and Therapy (5 papers). The work is most often cited by research in Oncology (691 citations), Immunology (469 citations) and Transplantation (55 citations). Dipak Datta has collaborated with scholars based in India, United States and Germany. Frequent co-authors include Soumitro Pal, David M. Briscoe, Akhilesh Singh, Sanjeev Meena, Anup K. Singh, Olivier Dormond, Aninda Basu, Ana Maria Waaga-Gasser, Rakesh Arya and Mushtaq Ahmad Nengroo. Their work appears in journals such as Cancer Research, Scientific Reports, Journal of Biological Chemistry, Organic & Biomolecular Chemistry and Cell Death and Disease.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026